Aditya Bardia, MD, MPH, FASCO
Articles by Aditya Bardia, MD, MPH, FASCO
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Funda Meric-Bernstam, MD,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Takahiro Kogawa 9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD 26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)
ByVirginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH, FASCO,Phillippe Aftimos,Javier Cortes,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,François-Clément Bidard 28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies
ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH, FASCO,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD 31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy
ByAditya Bardia, MD, MPH, FASCO,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MD 48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study
BySara M. Tolaney, MD, MPH,Peter Schmid, MD,Javier Cortes,Frederik Marmé,Hope S. Rugo, MD,Mafalda Oliveira,Delphine Loirat,Komal Jhaveri,Oh Kyu Yoon,Monica Motwani,Hao Wang,Rosemary Delaney,Aditya Bardia, MD, MPH, FASCO 53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Frederik Marmé,Javier Cortes,Peter Schmid, MD,Delphine Loirat,Olivier Trédan,Eva Ciruelos,Florence Dalenc,Patricia Gómez Pardo,Komal L. Jhaveri,Rosemary Delaney,Theresa Valdez,Hao Wang,Wendy Verret,Sara M. Tolaney, MD, MPH 55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy 54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)
ByHope S. Rugo, MD,Joyce O'Shaughnessy, MD,Komal Jhaveri,Sara M. Tolaney, MD, MPH,Fatima Cardoso,Aditya Bardia, MD, MPH, FASCO,Purnima Pathak,Sina Haftchenary,Peter A. Fasching 
Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.
Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.
Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.
Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.
Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.
In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.
Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.
Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.
Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.
Experts discussed the changing landscape in treatments for HER2-positive metastatic breast cancer.
Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.
Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.
Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.
In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.
Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.
